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Abstract 
Cancer recurrence typically brings a decline in physical functioning and feelings of 
hopelessness (HS). Social support (SS) may buffer the effects of hopelessness. The 
contribution of HS and SS and their interaction at the time of diagnosis to patients’ later 
physical status was tested. METHOD: Patients diagnosed with breast cancer recurrence were 
assessed after diagnosis and at 4 and 10 month follow-ups.  The outcome was a composite 
measure of physical status, including performance status, signs/symptoms of treatment 
toxicities, fatigue, and quality of life disruption due to physical symptoms. In addition to 
baseline physical status, predictors were HS and SS. RESULTS: Using hierarchical multiple 
regression, HS predicted poorer physical status at both 4- (β = -.34, p < .01) and 10-months 
(β = -.30, p < .05). Patients’ marital status predicted physical status at 4- months (β = .19, p 
< .05) but not at 10-months. The interaction effect of HS and perceived social support from 
family predicted physical status at 4-months (β = -.22, p < .05). CONCLUSIONS: 
Hopelessness predicted subsequent poorer physical status months later. There was little 
evidence that this effect was lessened by concurrent social support. 
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Cancer recurrence typically brings difficult treatments, declining health from either 
progressive disease or the treatments (Oh et al., 2004), and the potential for a lowered quality of 
life. Cross sectional studies have found that women with breast cancer recurrence show 
significantly more physical symptoms after a recurrence diagnosis than before (Bull et al., 1999), 
and that recurrence patients show worse physical functioning than disease-free survivors or 
women currently in treatment for an initial diagnosis (Frost et al., 2000). In a controlled 
longitudinal study of women with breast cancer, physical status significantly declined between 
initial and recurrence diagnosis (Andersen, Shapiro, Farrar, Crespin, Wells-DiGregorio, 2005). 
Along with declining physical functioning, breast cancer recurrence is also associated 
with psychological distress (Andersen et al., 2005; Mahon, Cella, & Donovan, 1990) including 
hopelessness (Koopman et al., 2001; Moore, Chamberlain, & Khuri, 2004; Noor-Mahomed, 
Schlebusch, & Bosch, 2003). Beck, Weissman, Lester, and Trexler define hopelessness as a 
person’s negative expectancies for himself and for his future (1974). Farran, Herth, and Popovich 
further explain this construct by elaborating on the three components of hopelessness- affective, 
cognitive, and behavioral (1995). Affective hopelessness can be thought of as a general feeling 
of despair, cognitive as pessimistic thinking (ex. thinking “I’m not going to survive this illness”), 
and behavioral as actions influenced by affective and cognitive hopelessness (ex. giving up an 
active role in treatment because of the belief that one has no control over her future).  Abramson, 
Metalsky, and Alloy go further to hypothesize that hopelessness is the cause of hopelessness 
depression (1989), which is a proposed subtype of depression.  
 Declining physical status may lead to increased hopelessness. This relationship has been 
found in breast cancer recurrence patients (Okano et al, 2001), those with other life threatening 
diseases (van Servellen, Sarna, Padilla, & Brecht, 1996), and among outpatients (Taniguchi, 
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Akechi, Suzuki, Mihara, & Uchitomi, 2003; Akechi, Okamura, Yamawaki, & Uchitomi, 1998). 
Increased hopelessness was significantly correlated with fatigue in ambulatory AIDS patients 
(Breitbart, McDonald, Rosenfeld, Monkman, & Passik 1998), and quality of life disruption due 
to physical symptoms in recurrent breast cancer patients (Northouse et al, 2002)  
 One mechanism thought to buffer the effects of hopelessness is social support (Abramson 
et al., 1989). Social support is associated with decreased psychological distress in recurrent 
cancer patients (Northouse, Laten, & Reddy, 1995; Parker, Baile, De Moor, & Cohen., 2003; 
Worden, 1989). However, a longitudinal study suggests that this effect may be short-lived- social 
support predicted psychological distress six months but not at 12-months for recurrent breast 
cancer patients in a study by Koopman, Hermanson, Diamond, Angell, & Spiegel (1998). In 
addition, more social support may be indirectly related to less hopelessness. A study found that 
among women with recurrent breast cancer, patients with more support reported less 
hopelessness and better mental and physical quality of life (Northouse et al., 2002). In summary, 
the literature suggests that recurrent patients experience declining physical functioning and 
hopelessness. Social support may act as a buffer, sheltering patients from distress.  
Focus of the present investigation 
 While there is literature suggesting that decreased physical functioning leads to increased 
hopelessness, the converse relationship has not been tested. This investigation tests if feelings of 
hopelessness at the time of a breast cancer recurrence diagnosis predict worsened physical status 
four and ten months later. The study also investigated whether the presence of social support 
could predict better physical status. Lastly, the interaction of hopelessness and social support 
were tested.  
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Method 
Procedure 
 Patients diagnosed with a breast cancer recurrence within the prior three months were 
eligible. Participants were recruited from a university-affiliated Comprehensive Cancer Center. 
Exclusion criteria were the following: prior/current refusal of treatment, prior diagnosis of other 
(non-breast) cancers, mental retardation, severe or untreated psychiatric disorders (e.g. 
schizophrenia, bipolar or borderline personality disorder), neurological or dementia disorders 
(e.g. Parkinson’s), and/or autoimmune disorders (e.g. Lupus or Crohn’s disease). Following the 
initial assessment patients were followed and reassessed 4 months, and 10 months later.  
Of the 147 patients eligible, 112 (76%) participated in the study and completed the initial 
assessment. Of these, 75 (67%) completed the 4-month assessment and 70 (63%) completed the 
10-month assessment. Between 4-months and 10-months, 17 (15%) people had a second 
recurrence or died, 17 (15%) dropped out of the study, and 8 (7%) were non-compliant. Women 
were given $50 for each completed assessment and parking reimbursement. 
Participants 
 Of the 112 women who completed the assessment at baseline, on average, the 
participants had been disease free (calculated as the time between initial and recurrence 
diagnosis) for 51 months (SD = 47 months) and 68% had distant metastases. See Table 1 for 
disease treatment information of the sample and Table 2 for socio-demographic information. 
Measures 
Hopelessness. The Beck Hopelessness Scale (HS; Beck et al., 1974) measures a person’s 
optimism or pessimism at present and for the future. It contains 20 items on a true-false scale. 
Examples of items include “I look forward to the future with hope and enthusiasm” and “My 
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future seems dark to me”. Total scores can range from 0 to 20, with higher scores indicating 
more hopelessness. Hopelessness was measured at baseline. Its alpha reliability for this study’s 
sample is .87. 
Social Support. Four measures were used. (1) Social Network Index. (SNI; Berkman, 
1977).  The SNI has 10 items pertaining to the number of and degree of involvement with 
various social networks. In particular it concentrates on four social components- marital status, 
number of close friends and relatives and frequency of monthly contact with these individuals, 
church group membership, and membership in other groups. When the total score is calculated, 
intimate contacts are given more weighting than group membership. SNI scores range from 1 to 
12, with a higher score indicating more social involvement. (2) Partner status (SO).  Among 
other sociodemographic and personal information, participants were asked whether or not they 
were currently living with a romantic partner. Those with a partner were assigned the score of 1 
and those without, 0. (3-4) Perceived Social Support from Family and Friends. (PSS-Fa & PSS-
Fr; Procidano & Heller, 1983). These are 20-item measures assessing perceived support from 
family and friends. Total scores range from 0 to 20, with a higher score indicating more 
perceived social support. The alpha reliability for PSS-Fam for this study’s sample is .93 and for 
PSS-Fr is .84. 
 Physical status. Four measures were used. (1) Karnofsky Performance Scale. (KPS; 
Karnofsky & Burchenal, 1949). This was used to measure performance status. The KPS 
ascertains a person’s physical performance on an 11-point Likert- scale.  KPS scores ranges from 
100 (Normal, no complaints, no evidence of disease) to 0 (Dead) and has 10 point increments. A 
lower score indicates a lower ability to take care of oneself and perform daily activities. This 
measure was assessed by a research nurse. Across cancer studies, interrater reliability for the 
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scale ranges from .70 to .97 (Mor, Laliberte, Morris, & Wiemann, 1984; Yates, Chalmer, & 
McKegney, 1980). (2) Fatigue Symptom Inventory. (FSI; Hann et al, 1998). The FSI has a total 
of 14 items that measure the severity, frequency, and perceived interference of fatigue on quality 
of life. A Disruption Index is calculated by using 7 items that ask about the perceived 
interference of fatigue on daily activities (such as bathing, dressing, and working) and quality of 
life. Items in this dimension are measured on an 11-point Likert scale ranging from 0 (No 
interference) to 10 (Extreme Interference). For this study, the Disruption Index was calculated by 
finding the average of the ratings of these seven items. Total scores range from 0 to 10 with a 
higher score indicating greater fatigue interference. Its alpha reliability for this study’s sample is 
0.95. (3) Southwest Oncology Group criteria. (Sym/S; Moinpour et al., 1989).  A research nurse 
recorded signs and symptoms of treatment toxicities using many of the criteria from the 
Southwest Oncology Group. The criteria look into toxicity symptoms in many body systems 
such as circulatory, cardiac, lung, neurological, etc, particularly as a result of chemotherapy 
treatment. Each symptom is rated for its severity, with a higher score indicating worse symptoms 
or toxicity. The possible scores for most items range from 0 to 4; however some items have a top 
score of 1, 2 or 3. For this study, the average score was found for each body system and then 
these were used to find a total average score. (4) Medical Outcomes Study 36-Item Short Form. 
(MOS-SF-36; Ware & Sherbourne, 1992). The MOS-SF-36 has 36 items relating to physical and 
mental quality of life. 8 subscales can be calculated from this measure, from the dimensions 
including physical functioning, role functioning related to physical health, bodily pain, general 
health perceptions, vitality, social functioning, role functioning related to emotional health, and 
mental health. Each of these subscales have scores from 0 to 100, with a higher score indicating 
a better quality of life. From these 8 subscales, 2 component summary scores can be calculated- a 
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Physical Component Summary (PCS) and a Metal Component Summary (MCS). For the purpose 
of this study, the PCS score was used. The PCS score is calculated by differentially weighing and 
aggregating subscale scores, giving positive weight to subscales that reflect physical quality of 
life and negative weight to mental. These aggregate scores are then standardized based on the 
general U.S. population of MOS-SF-36 scores.  
Analytic Strategy 
For primary analyses, a composite physical status variable of the four physical status 
measures was computed. First, scores from the FSI and Sym/S were reversed so that a higher 
score on all indices would indicate better physical status. Second, the scores were then 
standardized to have a mean of 0 and a standard deviation of 1. Finally, the composite physical 
status score was calculated by using the average of the four standardized scores. Bivariate 
correlations of physical status, socio-demographics, disease characteristic, and disease treatment 
variables are reported in Table 3. Variables that were significantly correlated with physical status 
were identified as control variables for hierarchical multiple regression analyses.  
Hierarchical multiple regression was used. Physical status at the 4-month or 10-month 
time-point were the dependent variables and the predictors were entered in the following order- 
step 1- control variables (ie. employment status, presence of distant metastasis) step 2- physical 
status at baseline, step 3- hopelessness at baseline, step 4- social support at baseline step 5- the 
interaction of  social support and hopelessness.  
Follow up analyses were conducted to identify if there were any specific predictors out of 
the four measures used to measure physical status (KPS, Sym/S, FSI, PCS) that were 
contributing to any effects observed in the primary analyses. The same plan for variable entry 
was used as for the primary analyses 
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Results 
Clinical description of the sample  
At initial, total scores on the HS ranged from 0 to 19 with a mean score of 3 (SD = 4); 
25% of the women scored at or above the cut-off score of 4 that indicates hopelessness.  (Beck et 
al., 1974).   
The average interference from fatigue in daily activities did not change significantly over 
the assessment period (Table 4), however the percentage of women who indicated that they 
experienced moderate to extreme fatigue disruption (a cutoff of 5) declined over the assessment 
period.  At baseline, 24% reported moderate to extreme fatigue, 20% at 4-months, and 11% at 
10-months. The average severity of signs and symptoms of treatment toxicities (Sym/S), and the 
nurse-assessed physical performance of the participants (KPS) did not change significantly over 
the assessment period (Table 4). The quality of life disruption due to physical symptoms (PCS) 
did not change significantly over the assessment period, however the means of this cancer 
sample are lower than that of the general US population (Mean = 50, SD = 10) and cancer 
patients in validation samples (Mean = 45.1, SD = 11.6). 
 Bivariate correlations (see Table 3) identified control variables for inclusion in the 
regression analyses.  Socio-demographic, disease characteristic variables, and disease treatment 
variables that were significantly correlated with physical status were included in the analyses. 
This was done so that any observed contribution of hopelessness or social support was above and 
beyond the contributions of the control variables. 
Multiple Regression Analyses 
All models with the physical status at 4-months as the dependent variable were 
significant. In each, hopelessness was a significant predictor accounting for 53% of the total 
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variance (total adjusted R2 = .51). Two of the social support and interaction variables were 
significant predictors (SO: β = .190, p = .033; PSS-Family X hopelessness: β = -.217, p = .033). 
The remaining social support and interaction variables were not significant predictors. (SNI and 
SNI X hopelessness: β = .068, p = .461 and β = .030, p = .796;  PSS-Friends and PSS-Friends X 
hopelessness: β = -.682, p = .498 and β = -1.470, p = .146; PSS-Family: β = .048, p = .582;  SO 
X hopelessness: β = -.001, p = .992) (see Table 5).  
Follow-up analyses indicated that hopelessness significantly predicted FSI (β = .230, p = 
.036),  KPS (β = -.292, p = .006), and Sym/S (β = .29, p=.003); see Table 7.  
The interaction of PSS-Family was evaluated further by dichotomizing hopelessness and 
PSS-Fam, using the cutoff score of 4 to indicate hopelessness, as recommended by Beck et al. 
(1974) and the score of 18 to indicate less than ideal family support, based on the median of all 
of the PSS-Fam scores. The residualized change of physical status at 4-months was calculated 
and this was graphed with the dichotomized scores (Fig. 1). The interaction indicates that the 
women at greatest risk for worse physical status at 4-months were those who reported greater 
feelings of hopelessness at diagnosis and who perceived low levels of social support from their 
family.  
All models with the physical status at 10-months as the dependent variable were 
significant. In each, hopelessness was a significant predictor accounting for 41% of the total 
variance (total adjusted R2 = .39). None of the social support indices, nor their interactions with 
hopelessness, were significant predictors when added to the model (SNI: β = -.047, p = .654; SNI 
X hopelessness: β = -.116, p = .417; PSS-Fam: β = .057, p = .578; PSS-Fam X hopelessness: β = 
-.209, p = .082; PSS-Fr: β = .040, p = .707; PSS-Fr X hopelessness: β = -.235, p = .053; SO: β = 
.016, p = .876; SO X hopelessness: β = -.133, p = .295) (see Table 6).      
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Follow-up analyses indicated that hopelessness significantly predicted FSI (β = .344, p = 
.004), and PCS (β = -.224, p = .049); see Table 8. 
Discussion 
 These results indicate that feelings of hopelessness in response to a diagnosis of breast 
cancer recurrence can be especially burdensome to a woman’s physical status. In this study, 
hopelessness predicted subsequent poorer physical status months later. This effect was seen not 
only in patient-rated, but nurse-rated physical status measures as well, such as the Karnofsky 
Performance Scale and signs/symptoms of treatment toxicities. In particular, hopelessness 
significantly predicted fatigue up to 10 months after diagnosis, physical performance and 
symptoms of treatment toxicity 4 months after diagnosis, and physical quality of life 10 months 
after diagnosis.  
The relation between fatigue and hopelessness upholds the findings of Breitbart et 
al.(1998) who found that hopelessness was significantly correlated with fatigue in a study of 
ambulatory AIDS patients. However, the relation between physical quality of life, as measured 
by the SF-36, and hopelessness contradicts the findings of Northouse et al. (2002) who found no 
such association between the two. On the other hand, although Northouse did not find this 
correlation, he did find through structural equation modeling that hopelessness moderates an 
effect between social support and physical quality of life. This is still contradictory to the results 
of this study, which found that social support did not significantly contribute to the regression 
model with physical quality of life as a predictor. One of the possible reasons for the difference 
in these studies is that Northouse’s study looked at physical quality of life at baseline, whereas 
the current study looked at it at 4 and 10-months. It is possible that there is a ceiling effect of 
social support; social support at baseline is beneficial but later either the support has reached its 
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maximum usefulness, or the patient’s support network is no longer providing as much support as 
it was initially. 
 This study had a number of strengths. Multiple measures of physical status were used, 
including two nurse-assessed measures. This increased the validity of the results, by combining 
data from an unbiased, skilled, rater with self-reported data. It also allowed us to look at multiple 
facets of physical status such as fatigue, physical performance, etc. Initial physical status was 
controlled in the study, thus ensuring that there was a true effect of hopelessness on future 
physical status, and the results were not because women with breast cancer recurrence often face 
a decline in physical functioning (Oh et al., 2004). Multiple measures of social support were also 
used, including both structural measures (e.g., presence of a significant other, numbers of family 
members and friends) and functional measures (e.g., patients’ perceptions of support from 
others). The final strength of this study was that it was longitudinal. Most of the prior literature 
on hopelessness and physical status report on cross-sectional studies. Whereas prior literature 
suggested an association between hopelessness and physical status, this study tests hopelessness 
as a predictor of future physical status.  
 The major weakness to this study was that the study sample was not representative of the 
total population of women who have had a breast cancer recurrence in the US. Our sample 
consisted overwhelmingly of Caucasian women with an above-average income and a higher than 
average amount of education. This may limit the generalizability of these results to other 
races/ethnicities and socioeconomic groups. For example, African-American women have a 
higher mortality rate from breast cancer than Caucasian women, and are more likely to be 
diagnosed with larger tumors (American Cancer Society, 2005). Lower income women also have 
higher breast cancer mortality rates and are more likely to be diagnosed with more advanced 
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disease (Baquet & Commiskey, 2000; O’Malley, Le, Glaser, Shema & West, 2003; Miller, 
Hankey & Thomas, 2002). This may suggest that African-American women and women of a 
lower socioeconomic status with recurrent cancer, experience worse physical status in the 
months following diagnosis than their Caucasian and higher socioeconomic counterparts.  
 These findings have clinical implications. Women diagnosed with a breast cancer 
recurrence may experience less decline in physical status if their initial hopelessness can be 
decreased. The Beck Hopelessness Scale can be administered by a nurse in order to identify 
hopeless breast cancer recurrence patients who may benefit from an intervention.  
 Future studies could design an intervention to decrease hopelessness upon cancer 
recurrence diagnosis, and then test if a decrease in hopelessness has a positive effect on future 
physical status.  One such intervention that has effectively been used is the Hope Intervention 
(HIP; Herth, 2001) The HIP instills hope in individuals with recurrence through establishing 
connectedness with others, identifying threats to hope, encouraging utilization of social support 
and community resources, reflecting on the meaning of life, and nurturing internal resources 
such as optimism. Future studies can also test to see if hopelessness can predict physical status 
for other cancer types, and if these patients’ physical status may also benefit from interventions 
targeting hopelessness. 
 In conclusion, feelings of hopelessness upon breast cancer recurrence diagnosis are a 
significant predictor of future physical status, and social support does little to buffer this effect. 
Patients’ physical status may benefit as a result of interventions targeted toward alleviating 
hopelessness.  
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Table 1 
Cancer treatments received during baseline and 4 and 10- month assessments 
 
 
 
 
 
 
 
 
 
 
 
Time-point In Treatment Type  
  Surgery Chemotherapy Tamoxifen Radiation 
Baseline 84% 29% 44% 31% 22% 
      
4-months 86% 3% 56% 39% 5% 
      
10-months 83% 3% 41% 51% 6% 
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Table 2 
 
Baseline socio-demographic characteristics of the sample (N=112). 
 
   
      
      
      
      
      
         
 
Variable Percent Minimum Maximum Mean Standard 
Deviation 
Employed 46% -- -- -- -- 
Have significant other 70% -- -- -- -- 
Caucasian 92% -- -- -- -- 
Age (Years) -- 30 89 59 11 
Education (Years)  -- 9 22 15 3 
Annual household income 
(Thousands) 
-- 5 500 68 60 
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Table 3 
 
Correlation matrix of all variables in study 
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 Sociodemographics  
1 Age (Yrs)                             
2 Ed -.108                            
3 Employeda -.271 -.091                           
4 Raceb .036 -.036 -.145                          
 Disease/Treatment  
5 Stagec -.126 .167 -.068 -.08                      
6 In Treatmenta -.127 .050 .127 .133 .043                     
7 DFId .282 -.042 -.087 .203 -.201 .002                     
8 Local metsa .105 -.065 -.058 -.167 -.333 -.190 .032                     
9 Distant metsa -.047 .055 .028 .137 .293 .250 -.048 -.883                     
 Physical status (at baseline)  
10 Composite    -.110 -.034 .199 -.213 .028 .113 .038 .162 -.168                
11 Sym/S .247 -.021 -.134 .13 .15 -.128 .048 -.074 .045 -.701                
12 KPS -.144 .023 .199 -.167 -.013 .085 .068 .146 -.198 .746 -.352                
13 FSI -.078 .113 -.109 .285 -.036 -.086 -.049 -.151 .148 -.816 .385 -.472                
14 PCS .072 -.04 .98 -.135 .078 -.002 .037 .154 -.153 .803 -.371 .454 -.639                
 Physical status (at 4-months)  
15 Composite .015 -.103 .243 -.135 -.024 -.024 -.057 .147 -.188 .69 -.477 .489 -.540 .536             
16 Sym/S .018 .12 -.143 .167 -.003 -.117 -.041 -.067 .09 -.610 .552 -.400 .496 -.344 -.778             
17 KPS -.055 -.075 .268 -.044 -.05 .078 -.09 .086 -.154 .435 -.288 .409 -0.237 .348 .805 -.458            
18 FSI -0.04 .015 -.154 .241 -.015 .029 .004 -.066 .021 -.646 .444 -.409 .594 -.488 -.835 .598 -.434           
19 PCS .019 -.134 .133 -.097 -.009 -.095 -195 .28 -.359 .592 -.289 .448 -.386 .608 .834 -.454 .640 -.597           
 Physical status (at 10-months)  
20 Composite -.035 .022 .16 -.151 -.066 .097 .058 .106 -.183 0.596 -.453 -.461 -.534 .368 0.668 .483 .417 -.646 .642      
21 Sym/S .11 .048 -.087 .084 .026 -.263 .014 .005 .053 -.568 .620 -.374 .400 -.330 -.57 .513 -.339 .476 -.474 -.802      
22 KPS -.077 .073 .193 -.224 .002 .056 .065 .229 -.346 .532 -.316 .450 -.497 .378 .565 -.366 .352 -.588 .575 .848 -.618      
23 FSI -.093 -.024 -.097 .128 .131 -.096 -.205 -.038 .06 -.425 .285 -.303 .503 -.247 -.488 .395 -0.206 .577 -.324 -.779 .488 -.507      
24 PCS -.042 .088 .111 -.1 -.084 -.077 -.066 .189 -.240 .419 -.249 .328 -.365 .336 .539 -.265 .392 -.414 .710 .839 -.525 .653 -.564      
 Predictors (at baseline)  
25 Hopelessness .032 -.034 -.011 -.041 .107 -.234 .08 -097 .078 -.384 .273 -.250 .411 -.209 -.443 .389 -.338 .426 -.255 -.395 .318 -.172 .474 -.259  
26 SNI  -.14 .157 .16 -.155 .046 .013 .006 .007 -.039 .169 -.124 0.074 -.230 0.129 .32 -.291 .292 -.112 .213 .155 -.092 .052 -.079 .142 -.265  
27 PSS-Family  .029 .067 .016 -.123 .087 -.051 .047 -.007 .047 .056 -0.007 0.1 -0.12 -.036 .049 0.026 0.075 -0.09 .033 .134 -0.045 -0.02 -0.198 .171 -.264 .426  
28 PSS-Friends -.106 .096 -.001 .049 -.013 .263 .145 .052 -.03 .056 -.017 0.072 0.062 0.067 .023 .037 0.17 .045 .008 -.002 -.01 -.132 -0.1 .022 -.315 .300 .391  
29 SO Statuse  -.297 .069 .148 -.305 -.028 -.016 -.203 .019 -.069 .232 -.119 .226 -.225 .156 .387 -.310 .351 -.188 .306 .2 -.151 .177 -.037 .198 -.178 .567 .164 .034
 
a 0=No, 1=Yes; b 1=Caucasian, 2=Minority; c 1=Stage I,  2=Stage II, 3=Stage III; d Disease Free Interval- Time between original and recurrence diagnosis (months); e 0=No Partner, 1=Partner; Bold = p 
< .05; Ed=Years of education; Local Mets= Local Metastasis; Distant Mets= Distant Metastasis; SYM/S = Southwest Oncology Group Criteria; KPS = Karnofsky Performance Status; FSI = Fatigue 
Symptom Index; PCS= Physical Component Score; SNI = Social Network Index; PSS = Perceived Social Support; SO = Significant Other 
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Table 4 
 
Descriptive statistics for outcome variables across time 
Measure  Time-Point Minimum Maximum Mean Standard 
Deviation 
Baseline 0 9 3 2 
4-months 0 10 3 2 FSI 
10-months 0 9 2 2 
Baseline .05 .54 .27 .11 
4-months .05 .75 .28 .14 Sym/S 
10-months .06 .51 .25 .11 
Baseline 40 100 77 11 
4-months 20 100 78 12 KPS 
10-months 40 100 79 12 
Baseline 13 58 37 10 
4-months 17 65 39 12 PCS 
10-months 16 60 39 12 
Hopelessness and Physical Status      22 
22 
Table 5 
Regression models with physical status at 4-months as the dependent variable 
 
 Statistics by Step Statistics by Predictor 
Step and Predictor TR2 R2 Change β t 
Outcome: Physical status at 4-months (Model 1) 
1. Employed at baselinea .05 .05† .13 1.44 
2. Physical Status at baseline .47 .42*** .56 5.92*** 
3.  Hopelessness (HS)  .53 .06** -.21 -1.68 
4.  SNI .53 .00 .07 .74 
5.  Hopelessness X SNI .53 .00 .03 .26 
Outcome: Physical status at 4-months (Model 2) 
1. Employed at baselinea .05 .05† .19 2.20* 
2. Physical Status at baseline .47 .42*** .53 5.72*** 
3.  Hopelessness (HS)  .53 .06** -.37 -3.42*** 
4.  PSS-Family  .53 .00 .05 .55 
5.  Hopelessness X PSS-Family  .56 .03* -.22 -2.17** 
Outcome: Physical status at 4-months (Model 3) 
1. Employed at baselinea .05 .05† .18 2.08* 
2. Physical Status at baseline .47 .42*** .53 5.81*** 
3.  Hopelessness (HS)  .53 .06** -.38 -3.45*** 
4.  PSS-Friends  .54 .01 -.06 -.68 
5.  Hopelessness X PSS-Friends .55 .01 -.16 -1.47 
Outcome: Physical status at 4-months (Model 4) 
1. Employed at baselinea .05 .05† .11 1.25 
2. Physical Status at baseline .47 .42*** .52 5.74*** 
3.  Hopelessness (HS)  .53 .06** -.23 -2.38* 
4.  Significant Other Status (SO)  .56 .03* .19 2.18* 
5.  Hopelessness X SO .56 .00 .00 .00 
a 0=No, 1=Yes;  † p = .06, * p < .05,  ** p < .01, *** p < .001  
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Table 6 
Regression models with physical status at 10-months as the dependent variable 
 
 Statistics by Step Statistics by Predictor 
Step and Predictor TR2 R2 Change β t 
Outcome: Physical status at 10-months (Model 1) 
1.  Physical Status at baseline .26 .36*** .52 4.94*** 
2.  Hopelessness (HS)  .41 .05* -.34 -2.26* 
3.  SNI  .41 .00 -.05 -.45 
4.  Hopelessness X SNI .42 .01 -.12 -.82 
Outcome: Physical status at 10-months (Model 2) 
1.  Physical Status at baseline .26 .36*** .50 4.92*** 
2.  Hopelessness (HS)  .41 .05* -.34 -2.81** 
3.  PSS-Family  .41 .00 .06 .56 
4.  Hopelessness X PSS-Family  .44 .03 -.21 -1.77 
Outcome: Physical status at 10-months (Model 3) 
1.  Physical Status at baseline .26 .36*** .50 5.00*** 
2.  Hopelessness (HS)  .41 .05* -.35 -3.02** 
3.  PSS-Friends  .41 .00 .04 .38 
4.  Hopelessness X PSS-Friends .44 .03† -.24 -1.97† 
Outcome: Physical status at 10-months (Model 4) 
1.  Physical Status at baseline .26 .36*** .52 5.04*** 
2.  Hopelessness (HS)  .41 .05* -.32 -2.43* 
3.  Significant Other Status (SO)  .41 .00 .02 .16 
4.  Hopelessness X SO .42 .01 -.13 -1.06 
† p = .06, * p < .05,  ** p < .01, *** p < .001  
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Table 7 
Regression models for follow-up analyses with dependent at 4-months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 0=No, 1=Yes;  † p = .06, * p < .05,  ** p < .01, *** p < .001  
 Statistics by Step 
 
Statistics by Predictor 
Step and Predictor TR2 R2 Change β t 
Outcome: Fatigue Symptom Inventory (FSI) at 4-months 
1.  FSI at baseline .37 .37*** .51 4.74*** 
2.  Hopelessness (HS) .42 .04* .23 2.15* 
Outcome: Karnofsky Performance Scale (KPS) at 4-months 
1.  Employed at baselinea .06 .06* .22 2.12* 
2.  KPS at baseline .19 .13*** .30 2.84** 
3.  Hopelessness (HS)  .27 .08** -.29 -2.80** 
Outcome: Physical Component Score of SF-36 (PCS) at 4-months 
1. Local Metastasis a 
     Distant Metastasis a 
.16 .16** -.05 
-.36 
-.27 
-1.83 
2.  PCS at baseline .48 .31*** .54 5.85*** 
3.  Hopelessness (HS)  .49 .02 -.13 -1.44 
Outcome: Signs and Symptoms of Treatment Toxicities (Sym/S) at 4-months 
1. Sym/S at baseline .30 .30*** .47 4.91*** 
2. Hopelessness (HS)  .38 .08** .29 3.04** 
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Table 8 
Regression models for follow-up analyses with dependent at 10-months 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 0=No, 1=Yes;  † p = .06, * p < .05,  ** p < .01, *** p < .001  
 Statistics by Step Statistics by 
Predictor 
Step and Predictor TR2 R2 Change β t 
Outcome:  Fatigue Symptom Inventory (FSI) at 10-months 
1.  FSI at baseline .25 .25*** .37 3.23** 
2.  Hopelessness (HS)  .35 .10** .34 3.04** 
Outcome:  Karnofsky Performance Scale (KPS) at 10-months 
1. Distant Metastasis a .11 .11** -.25 -2.33** 
2.  KPS at baseline .26 .15*** .38 3.48*** 
3.  Hopelessness (HS)  .28 .02 -.13 -1.18 
Outcome:  Physical Component Score of SF-36 (PCS) at 10-months 
1. Distant Metastasis a .06 .06* -.19 -1.69 
2.  PCS at baseline .16 .10** .30 2.67* 
3.  Hopelessness (HS)  .21 .05* -.22 -2.01* 
Outcome: Signs and Symptoms of Treatment Toxicities (Sym/S) at 10-months 
1.  Sym/S at baseline .39 .39*** .58 5.82*** 
2.  Hopelessness (HS)  .40 .01 .13 1.25 
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Figure 1.  
 
Interaction effect of Hopelessness and Perceived Social Support of Family (PSS-Fam) at 
baseline on Physical Status at 4-months.  
 
 
